Scientific Publications

Posters and Presentations

Tipifarnib

Tipifarnib is Highly Active in HRAS-mutant Lung Squamous Cell Carcinoma Tumor Models
AACR 2018 Poster

Pre-clinical Activity of Tipifarnib in Cutaneous T-cell Lymphoma
AACR 2018 Poster

Preliminary Results from a Phase 2 Trial of Tipifarnib in HRAS mutant Head & Neck Squamous Cell Carcinomas (HNSCC)
H&N 2018 Poster

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes
ASH 2017 Poster

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma
ASH 2017 Poster

Preliminary results from an open-label, phase 2 study of tipifarnib in chronic myelomonocytic leukemia (CMML)
ASH 2017 Poster

Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation
ASH 2017 Poster

Preliminary results from a phase 2 proof of concept trial of Tipifarnib in tumors with HRAS mutations.
AACR-NCI-EORTC 2017 Presentation

Preliminary results from a phase 2 proof of concept trial of Tipifarnib in tumors with HRAS Mutations.
AACR-NCI-EORTC 2017 Poster

Preliminary results from an open-label, phase II study of tipifarnib in relapsed or refractory peripheral T-cell lymphoma.
EHA 2017 Poster

Preliminary results from an open-label, phase II study of tipifarnib in relapsed or refractory peripheral T-cell lymphoma.
ICML 2017 Poster

Tipifarnib is Highly Active in HRAS-mutant SCCHN Tumor Models.
AACR Head and Neck 2017 Poster

Preliminary evidence of clinical activity with tipifarnib in squamous cell carcinomas of the head & neck (SCCHN) with HRAS mutations.
15th International Congress on Targeted Anticancer Therapies (TAT 2017) Presentation

Targeting the RAS-ERK Pathway.
9th European Scientific Oncology Conference (ESOC-9) Presentation

KO-947 / ERK

11q13 amplification selects for sensitivity to the ERK inhibitor KO-947 in squamous cell carcinomas
AACR 2018 Poster

KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors.
AACR 2017 Poster

KO-947, a Potent and Selective ERK Inhibitor with Slow Dissociation Kinetics.
EORTC 2016 Poster

Targeting the RAS-ERK Pathway.
9th European Scientific Oncology Conference (ESOC-9) 2016 Presentation

KO-539 / Menin-MLL

A Novel Small Molecule Menin-MLL Inhibitor for Potential Treatment of MLL-rearranged Leukemias and NPM1/DNMT3A-mutant AML.
AACR-EORTC-NCI 2017 Poster

A Novel Small Molecule Menin-MLL Inhibitor for Potential Treatment of MLL-rearranged Leukemias.
AACR 2017 Poster

Discovery of novel menin-MLL small molecule inhibitors that display high potency and selectivity in vitro and in vivo.
EORTC 2016 Poster

Publications

Tipifarnib

Protein farnesylation:

Cox, et al. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? Clin. Cancer Res, 21(8), 1819-1827 (April 2015)
Publication

Berndt, et al. Targeting protein prenylation for cancer therapy. Nature Reviews Cancer 11, 775-791 (November 2011)
Publication

HRAS:

Chen, et al. Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition. Oncogene, 33(47):5442-9 (2014 Nov 20)
Publication

PTCL:

Witzig, et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 2011 Nov 3; 118(18):4882-9
Publication

MDS:

Ghobrial, et al. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nature Reviews Clinical Oncology. 2018 Jan 9; 15, 219-233
Publication

Fenaux, et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood. 2007 May 15; 109(10):4158-63
Publication

CMML: